tetano
Editor, Senior Moderator
Clin Infect Dis. 2018 Oct 11. doi: 10.1093/cid/ciy876. [Epub ahead of print]
[h=1]Vaccine effectiveness against lineage matched and mismatched influenza B viruses across 8 seasons in Canada, 2010-11 to 2017-18.[/h] Skowronski DM[SUP]1,[/SUP][SUP]2[/SUP], Chambers C[SUP]1[/SUP], De Serres G[SUP]3,[/SUP][SUP]4,[/SUP][SUP]5[/SUP], Sabaiduc S[SUP]1[/SUP], Winter AL[SUP]6[/SUP], Dickinson JA[SUP]7[/SUP], Gubbay JB[SUP]6,[/SUP][SUP]8[/SUP], Drews SJ[SUP]9,[/SUP][SUP]10[/SUP], Fonseca K[SUP]7,[/SUP][SUP]11[/SUP], Charest H[SUP]3,[/SUP][SUP]12[/SUP], Martineau C[SUP]3,[/SUP][SUP]12[/SUP], Hickman R[SUP]1[/SUP], Chan T[SUP]1[/SUP], Jassem A[SUP]1,[/SUP][SUP]2[/SUP], Petric M[SUP]2[/SUP], Rose C[SUP]1,[/SUP][SUP]2[/SUP], Bastien N[SUP]13[/SUP], Li Y[SUP]13[/SUP], Krajden M[SUP]1,[/SUP][SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Vaccine effectiveness (VE) against influenza B was derived separately for Victoria and Yamagata lineages across eight seasons (2010-11 to 2017-18) in Canada when trivalent influenza vaccine was predominantly used. VE was ≥50% regardless of lineage match to circulating viruses, except when the vaccine strain was unchanged from the prior season.
PMID: 30312364 DOI: 10.1093/cid/ciy876
[h=1]Vaccine effectiveness against lineage matched and mismatched influenza B viruses across 8 seasons in Canada, 2010-11 to 2017-18.[/h] Skowronski DM[SUP]1,[/SUP][SUP]2[/SUP], Chambers C[SUP]1[/SUP], De Serres G[SUP]3,[/SUP][SUP]4,[/SUP][SUP]5[/SUP], Sabaiduc S[SUP]1[/SUP], Winter AL[SUP]6[/SUP], Dickinson JA[SUP]7[/SUP], Gubbay JB[SUP]6,[/SUP][SUP]8[/SUP], Drews SJ[SUP]9,[/SUP][SUP]10[/SUP], Fonseca K[SUP]7,[/SUP][SUP]11[/SUP], Charest H[SUP]3,[/SUP][SUP]12[/SUP], Martineau C[SUP]3,[/SUP][SUP]12[/SUP], Hickman R[SUP]1[/SUP], Chan T[SUP]1[/SUP], Jassem A[SUP]1,[/SUP][SUP]2[/SUP], Petric M[SUP]2[/SUP], Rose C[SUP]1,[/SUP][SUP]2[/SUP], Bastien N[SUP]13[/SUP], Li Y[SUP]13[/SUP], Krajden M[SUP]1,[/SUP][SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Vaccine effectiveness (VE) against influenza B was derived separately for Victoria and Yamagata lineages across eight seasons (2010-11 to 2017-18) in Canada when trivalent influenza vaccine was predominantly used. VE was ≥50% regardless of lineage match to circulating viruses, except when the vaccine strain was unchanged from the prior season.
PMID: 30312364 DOI: 10.1093/cid/ciy876